USA - NASDAQ:CLVR - CA1867602031 - Common Stock
The current stock price of CLVR is 3 USD. In the past month the price decreased by -26.74%. In the past year, price decreased by -60.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
Clever Leaves Holdings Inc is a CO-based company operating in Pharmaceuticals industry. The company employs 400 full-time employees The company went IPO on 2020-12-18. Clever Leaves Holdings Inc. is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids. The firm's segments include Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is comprised of cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of its acquisition of Herbal Brands. The Non-Cannabinoid segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceuticals, excluding cannabinoid products. Its customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States. The company offers product portfolio in two categories: nutraceuticals and cannabinoids. The nutraceutical products consist of a variety of beverage and powder products.
CLEVER LEAVES HOLDINGS INC
Bodega 19-B Parque Industrial Tibitoc Ph, Tocancipa - Cundinamarca
Boca Raton FLORIDA 10017 CO
CEO: Kyle Detwiler
Employees: 400
Phone: 16468804382.0
Clever Leaves Holdings Inc is a CO-based company operating in Pharmaceuticals industry. The company employs 400 full-time employees The company went IPO on 2020-12-18. Clever Leaves Holdings Inc. is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids. The firm's segments include Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is comprised of cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of its acquisition of Herbal Brands. The Non-Cannabinoid segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceuticals, excluding cannabinoid products. Its customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States. The company offers product portfolio in two categories: nutraceuticals and cannabinoids. The nutraceutical products consist of a variety of beverage and powder products.
The current stock price of CLVR is 3 USD. The price increased by 42.18% in the last trading session.
CLVR does not pay a dividend.
CLVR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CLVR stock is listed on the Nasdaq exchange.
6 analysts have analysed CLVR and the average price target is 24.48 USD. This implies a price increase of 716% is expected in the next year compared to the current price of 3.
CLEVER LEAVES HOLDINGS INC (CLVR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.4).
ChartMill assigns a fundamental rating of 2 / 10 to CLVR. CLVR may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CLVR reported a non-GAAP Earnings per Share(EPS) of -11.4. The EPS increased by 78.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.31% | ||
| ROE | -73.94% | ||
| Debt/Equity | 0.03 |
6 analysts have analysed CLVR and the average price target is 24.48 USD. This implies a price increase of 716% is expected in the next year compared to the current price of 3.
For the next year, analysts expect an EPS growth of 29.03% and a revenue growth 50% for CLVR